Poxel（PXXL.F）株式概要Poxel S.A.は臨床段階にあるバイオ医薬品会社で、代謝性疾患、2型糖尿病、肝疾患の新規治療薬を開発している。 詳細PXXL.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6報酬当社が推定した公正価値より67.5%で取引されている 過去5年間の収益は年間7.8%増加しました。 リスク分析マイナスの株主資本 株式の流動性は非常に低い 意味のある時価総額がありません ( $15M )すべてのリスクチェックを見るPXXL.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.26198.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-44m44m2016201920222025202620282031Revenue €1.6mEarnings €284.2kAdvancedSet Fair ValueView all narrativesPoxel S.A. 競合他社Harvard Apparatus Regenerative TechnologySymbol: OTCPK:HRGNMarket cap: US$24.6mCyclerion TherapeuticsSymbol: NasdaqCM:CYCNMarket cap: US$13.4mApollomicsSymbol: NasdaqCM:APLMMarket cap: US$31.4mBioAtlaSymbol: NasdaqCM:BCABMarket cap: US$6.0m価格と性能株価の高値、安値、推移の概要Poxel過去の株価現在の株価€0.2652週高値€0.2652週安値€0.26ベータ1.311ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化-68.67%5年間の変化-96.83%IPOからの変化-96.98%最新ニュースお知らせ • Apr 30Poxel S.A. to Report Fiscal Year 2025 Results on Jun 15, 2026Poxel S.A. announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Jun 15, 2026お知らせ • Nov 27Poxel S.A., Annual General Meeting, Dec 11, 2025Poxel S.A., Annual General Meeting, Dec 11, 2025. Location: 12 cours de verdun rambaud esplanade de la gare, lyon Franceお知らせ • Aug 01+ 1 more updatePoxel S.A. Announces Board ChangesPoxel SA announced significant changes within its Board of Directors following the filing for reorganization proceedings. All the current directors of the Company, Ms. Pascale Boissel, Mr. Richard Kender, Mr. Thomas Kuhn, and Mr. Khoso Baluch, submitted their resignations with immediate effect as of July 31, 2025. The Board of Directors decided to replace them individually by co-optation with immediate effect by the following new directors: Ms. Sophie Jacq Lapointe, Mr. Nicolas Trouche, Mr. Amit Kohli, and Mr. Alexandre Bragadir. These co-optations will be subject to ratification at the next general meeting of shareholders of the Company. Ms. Sophie Jacq Lapointe has been appointed by the new Board of Directors as Chairman of the Board of Directors, succeeding Mr. Khoso Baluch. Sophie Jacq Lapointe has over 20 years of experience in the pharmaceutical industry, having held numerous executive roles and contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology. She has led or been involved in more than twenty product launches in France, across Europe, and in emerging markets, during her time at Roche, Sanofi, and Ipsen. This includes major R&D transformation projects at Sanofi and Ipsen, as well as serving as General Manager for the Belgium–Luxembourg region at Ipsen and the biotech company Perha Pharmaceuticals. For the past two years, she has been advising biotech Chief Executive Officers and executive committees on clinical and commercial development of innovative product portfolios, with successful business development outcomes. Sophie holds a degree from ESSEC Business School. Amit Kohli has over 3 decades of leadership experience operating at the intersection of science, finance, and commercialization. Amit has extensive experience in the diabetes therapy area, having held senior roles at Sanofi (1997-2010) and Becton Dickinson (2011-2016) where he launched diabetes-related products across developed and emerging markets growing them to multi-billion euros in revenue. Lately, as Chief Executive Officer of privately held biotech, Antev (2020 onwards), he led the company’s $75M sale to Medicus. Mr. Kohli has held Global and regional leadership roles at Pharnext, Eurofins, Becton Dickinson, and Sanofi, encompassing sales, marketing, finance, supply chain, and manufacturing. Mr. Kohli earned an M.B.A. in Finance from the Management Development Institute (MDI) Gurgaon, in India, and a Bachelor of Mechanical Engineering from the University of Pune in India. Alexandre Bragadir has been a Senior Investment Director at IPF Partners, a fund specializing in non-dilutive financing for innovative healthcare companies across Europe. He structures and oversees debt investments, having been involved with a dozen companies in the biotech, biopharma, medtech, and digital health sectors over the past six years. He began his career in 2003 in audit at Salustro Reydel before joining BNP Paribas, in strategic client coverage in Portugal, in structured finance in Paris, and in the commodity trade finance team in Geneva. Alexandre holds a degree from ESCP Europe.お知らせ • May 28Poxel SA Announces New Clinical and Scientific Data on TWYMEEG® to Be Presented at the 68th Annual Meeting of the Japan Diabetes SocietyPOXEL SA announced that new clinical and scientific data on TWYMEEG will be presented at the 68th Annual Meeting of the Japan Diabetes Society (JDS 2025), taking place from May 29 to 31, 2025, in Okayama, Japan. A total of 15 presentations, including results from 7 clinical trials, 3 post-hoc analyses and 5 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. These findings further confirm TWYMEEG's efficacy in monotherapy and combination therapies, safety, dual mechanism of action and potential benefits in specific patient populations. Main topics include: TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) study (Phase 4 study): confirmation of TWYMEEG®? efficacy and safety in diabetic patients with renal impairment; FAMILIAR Study: confirmation of TWYMEE G®? efficacy and safety in combination with DPP-4 inhibitors; PARADIME Clamp: confirmation of TWYMeeG®? dual mechanism of action in diabetic patients - clinical data showing effects on insulin sensitivity (clamp part) and glucose stimulated insulin secretion (OGTT part); PARADIME TIR: confirmation of TWYMCEG®? effects on glucose variability; PET/MRI Study: confirmation of TWY MEEG®? effect on glucose excretion in the gut.お知らせ • Apr 08Poxel SA Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG®? Package Insert to Include Type 2 Diabetes Patients with Renal ImpairmentPOXEL SA announced that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved the revision of TWYMEEG®? package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m2. This approval follows positive topline results from the post-marketing clinical study TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) in Japanese type 2 diabetic patients with renal impairment, which confirmed TWYMEEG®®?'s safety and tolerability profile, as announced last August1. Based on these results, discussions with the Japanese regulatory authorities were initiated by Sumitomo Pharma, resulting in the approval that will be officially implemented by Sumitomo Pharma as of April 8, 2025.お知らせ • Jan 24+ 4 more updatesPoxel S.A. to Report First Half, 2025 Results on Sep 23, 2025Poxel S.A. announced that they will report first half, 2025 results on Sep 23, 2025最新情報をもっと見るRecent updatesお知らせ • Apr 30Poxel S.A. to Report Fiscal Year 2025 Results on Jun 15, 2026Poxel S.A. announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Jun 15, 2026お知らせ • Nov 27Poxel S.A., Annual General Meeting, Dec 11, 2025Poxel S.A., Annual General Meeting, Dec 11, 2025. Location: 12 cours de verdun rambaud esplanade de la gare, lyon Franceお知らせ • Aug 01+ 1 more updatePoxel S.A. Announces Board ChangesPoxel SA announced significant changes within its Board of Directors following the filing for reorganization proceedings. All the current directors of the Company, Ms. Pascale Boissel, Mr. Richard Kender, Mr. Thomas Kuhn, and Mr. Khoso Baluch, submitted their resignations with immediate effect as of July 31, 2025. The Board of Directors decided to replace them individually by co-optation with immediate effect by the following new directors: Ms. Sophie Jacq Lapointe, Mr. Nicolas Trouche, Mr. Amit Kohli, and Mr. Alexandre Bragadir. These co-optations will be subject to ratification at the next general meeting of shareholders of the Company. Ms. Sophie Jacq Lapointe has been appointed by the new Board of Directors as Chairman of the Board of Directors, succeeding Mr. Khoso Baluch. Sophie Jacq Lapointe has over 20 years of experience in the pharmaceutical industry, having held numerous executive roles and contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology. She has led or been involved in more than twenty product launches in France, across Europe, and in emerging markets, during her time at Roche, Sanofi, and Ipsen. This includes major R&D transformation projects at Sanofi and Ipsen, as well as serving as General Manager for the Belgium–Luxembourg region at Ipsen and the biotech company Perha Pharmaceuticals. For the past two years, she has been advising biotech Chief Executive Officers and executive committees on clinical and commercial development of innovative product portfolios, with successful business development outcomes. Sophie holds a degree from ESSEC Business School. Amit Kohli has over 3 decades of leadership experience operating at the intersection of science, finance, and commercialization. Amit has extensive experience in the diabetes therapy area, having held senior roles at Sanofi (1997-2010) and Becton Dickinson (2011-2016) where he launched diabetes-related products across developed and emerging markets growing them to multi-billion euros in revenue. Lately, as Chief Executive Officer of privately held biotech, Antev (2020 onwards), he led the company’s $75M sale to Medicus. Mr. Kohli has held Global and regional leadership roles at Pharnext, Eurofins, Becton Dickinson, and Sanofi, encompassing sales, marketing, finance, supply chain, and manufacturing. Mr. Kohli earned an M.B.A. in Finance from the Management Development Institute (MDI) Gurgaon, in India, and a Bachelor of Mechanical Engineering from the University of Pune in India. Alexandre Bragadir has been a Senior Investment Director at IPF Partners, a fund specializing in non-dilutive financing for innovative healthcare companies across Europe. He structures and oversees debt investments, having been involved with a dozen companies in the biotech, biopharma, medtech, and digital health sectors over the past six years. He began his career in 2003 in audit at Salustro Reydel before joining BNP Paribas, in strategic client coverage in Portugal, in structured finance in Paris, and in the commodity trade finance team in Geneva. Alexandre holds a degree from ESCP Europe.お知らせ • May 28Poxel SA Announces New Clinical and Scientific Data on TWYMEEG® to Be Presented at the 68th Annual Meeting of the Japan Diabetes SocietyPOXEL SA announced that new clinical and scientific data on TWYMEEG will be presented at the 68th Annual Meeting of the Japan Diabetes Society (JDS 2025), taking place from May 29 to 31, 2025, in Okayama, Japan. A total of 15 presentations, including results from 7 clinical trials, 3 post-hoc analyses and 5 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. These findings further confirm TWYMEEG's efficacy in monotherapy and combination therapies, safety, dual mechanism of action and potential benefits in specific patient populations. Main topics include: TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) study (Phase 4 study): confirmation of TWYMEEG®? efficacy and safety in diabetic patients with renal impairment; FAMILIAR Study: confirmation of TWYMEE G®? efficacy and safety in combination with DPP-4 inhibitors; PARADIME Clamp: confirmation of TWYMeeG®? dual mechanism of action in diabetic patients - clinical data showing effects on insulin sensitivity (clamp part) and glucose stimulated insulin secretion (OGTT part); PARADIME TIR: confirmation of TWYMCEG®? effects on glucose variability; PET/MRI Study: confirmation of TWY MEEG®? effect on glucose excretion in the gut.お知らせ • Apr 08Poxel SA Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG®? Package Insert to Include Type 2 Diabetes Patients with Renal ImpairmentPOXEL SA announced that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved the revision of TWYMEEG®? package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m2. This approval follows positive topline results from the post-marketing clinical study TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) in Japanese type 2 diabetic patients with renal impairment, which confirmed TWYMEEG®®?'s safety and tolerability profile, as announced last August1. Based on these results, discussions with the Japanese regulatory authorities were initiated by Sumitomo Pharma, resulting in the approval that will be officially implemented by Sumitomo Pharma as of April 8, 2025.お知らせ • Jan 24+ 4 more updatesPoxel S.A. to Report First Half, 2025 Results on Sep 23, 2025Poxel S.A. announced that they will report first half, 2025 results on Sep 23, 2025お知らせ • Nov 08Poxel S.A. Provides Revenue Guidance for the Full Year 2024Poxel S.A. provided revenue guidance for the full year 2024. The company to see the good sales trajectory for TWYMEEG in Japan, which should lead to the achievement of JPY 5 billion net sales in the coming months, at which point, Poxel will be entitled to 10% royalties on all TWYMEEG net sales and a sales-based payment of JPY 500 million (EUR 3.1 million).These amounts, based on recent royalty monetization agreement, will serve to start repayment of bonds to OrbiMed. Additionally, Poxel will benefit from the residual amount of the reserve deposit made under the terms of the agreement with OrbiMed, in addition to the USD 42.5 million proceeds received upon closing.お知らせ • Oct 24Poxel S.A., Annual General Meeting, Nov 28, 2024Poxel S.A., Annual General Meeting, Nov 28, 2024. Location: hotel mercure lyon, centre chateau perrache, 12 cours de verdun rambaud esplanade de la gare, lyon Franceお知らせ • Aug 07Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in JapanSumitomo Pharma Co., Ltd. and POXEL SA announced topline results obtained from a post-marketing clinical study, TWINKLE (TWYMEEG in diabetic patients with renal impairment: A post-marketing long-term study) (“the Study”), in Japanese type 2 diabetic patients with renal impairment for TWYMEEG Tablets 500 mg (generic name: imeglimin hydrochloride, “the Drug”) being sold in Japan, based on the Risk Management Plan. The Study was an open-label, uncontrolled, long-term study in 60 Japanese type 2 diabetic patients with renal impairment, who had no experience of type 2 diabetes treatment other than diet and exercise therapy or insufficient glycemic management in monotherapy with a hypoglycemic agent excluding insulin formulation. The Drugwas administered at 500 mg twice-daily to patients with moderate and severe renal impairment, characterized by an estimated glomerular filtration rate (eGFR) between 15 mL/min/1.73 m2 or higher to less than 45 mL/min/1.73 m2, or at 500 mg once-daily to patients with end-stage renal disease, characterized by an eGFR less than 15 mL/min/1.73m2, in monotherapy or in combination therapy with a hypoglycemic agent excluding insulin formulation, to evaluate safety and tolerability when administered orally for 52 weeks. The Drug was observed to be safe and well tolerated in Japanese type 2 diabetic patients with renal impairment and no significant differences were found in the incidence of adverse events, their types and severities in this study from previous clinical studies. Specifically, most of the adverse events were mild or moderate in severity. The incidence of serious adverse events was 16.7% (10 of 60 subjects) and causality with the Drug could be ruled out in all cases. Incidence of adverse events leading to study treatment discontinuation was also limited (4 of 60 subjects). At present, administration of the Drug is not recommended for patients with renal impairment with eGFR less than 45 mL/min/1.73m2. Based on the results of the Study, Sumitomo Pharma is planning to conduct discussions with the regulatory authorities in Japan, on revising the package insert in fiscal 20241 for patients with renal impairment with eGFR less than 45 mL/min/1.73m2.お知らせ • May 16Poxel S.A., Annual General Meeting, Jun 21, 2023Poxel S.A., Annual General Meeting, Jun 21, 2023, at 09:00 Central European Standard Time. Location: Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bonnel, 69003 LYON, France. Lyon Franceお知らせ • Jan 04+ 3 more updatesPoxel S.A. to Report Q3, 2023 Results on Nov 08, 2023Poxel S.A. announced that they will report Q3, 2023 results on Nov 08, 2023株主還元PXXL.FUS BiotechsUS 市場7D0%1.2%1.0%1Yn/a34.9%28.7%株主還元を見る業界別リターン: PXXL.FがUS Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: PXXL.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is PXXL.F's price volatile compared to industry and market?PXXL.F volatilityPXXL.F Average Weekly Movementn/aBiotechs Industry Average Movement11.0%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: PXXL.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のPXXL.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト20095Nicolas Trouchewww.poxelpharma.comPoxel S.A.は臨床段階にあるバイオ医薬品会社で、代謝性疾患、2型糖尿病、肝疾患の新規治療薬を開発している。同社の主力製品はTWYMEEG（イメグリミン）で、ミトコンドリア機能障害を標的とする経口薬候補であり、日本では2型糖尿病の治療薬として承認されている。また、アデノシン一リン酸活性化プロテインキナーゼ酵素であるPXL770も開発しており、非アルコール性脂肪肝炎（NASH）など肝臓に影響を及ぼす疾患を含む慢性代謝性疾患の治療薬として臨床第2a相試験中である。同社はEnyo Pharma S.A.S.とB型肝炎とNASHの治療薬としてフェーズ2a試験中のファルネソイドX受容体の開発、DeuteRx LLCとミトコンドリア機能障害治療薬PXL065の開発、住友製薬とImegliminの開発と商業化に関するライセンス契約を結んでいる。Poxel S.A.は2009年に設立され、フランスのリヨンに本社を置いている。もっと見るPoxel S.A. 基礎のまとめPoxel の収益と売上を時価総額と比較するとどうか。PXXL.F 基礎統計学時価総額US$14.95m収益（TTM）-US$15.84m売上高(TTM)US$8.88m1.7xP/Sレシオ-0.9xPER（株価収益率PXXL.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PXXL.F 損益計算書（TTM）収益€7.66m売上原価€3.67m売上総利益€3.98mその他の費用€17.65m収益-€13.66m直近の収益報告Jun 30, 2025次回決算日Jun 15, 2026一株当たり利益（EPS）-0.25グロス・マージン52.02%純利益率-178.45%有利子負債／自己資本比率-101.0%PXXL.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 14:33終値2026/03/27 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Poxel S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Jason ButlerCitizens JMP Securities, LLCDavid SeynnaeveDegroof PetercamPeter WelfordJefferies LLC5 その他のアナリストを表示
お知らせ • Apr 30Poxel S.A. to Report Fiscal Year 2025 Results on Jun 15, 2026Poxel S.A. announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Jun 15, 2026
お知らせ • Nov 27Poxel S.A., Annual General Meeting, Dec 11, 2025Poxel S.A., Annual General Meeting, Dec 11, 2025. Location: 12 cours de verdun rambaud esplanade de la gare, lyon France
お知らせ • Aug 01+ 1 more updatePoxel S.A. Announces Board ChangesPoxel SA announced significant changes within its Board of Directors following the filing for reorganization proceedings. All the current directors of the Company, Ms. Pascale Boissel, Mr. Richard Kender, Mr. Thomas Kuhn, and Mr. Khoso Baluch, submitted their resignations with immediate effect as of July 31, 2025. The Board of Directors decided to replace them individually by co-optation with immediate effect by the following new directors: Ms. Sophie Jacq Lapointe, Mr. Nicolas Trouche, Mr. Amit Kohli, and Mr. Alexandre Bragadir. These co-optations will be subject to ratification at the next general meeting of shareholders of the Company. Ms. Sophie Jacq Lapointe has been appointed by the new Board of Directors as Chairman of the Board of Directors, succeeding Mr. Khoso Baluch. Sophie Jacq Lapointe has over 20 years of experience in the pharmaceutical industry, having held numerous executive roles and contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology. She has led or been involved in more than twenty product launches in France, across Europe, and in emerging markets, during her time at Roche, Sanofi, and Ipsen. This includes major R&D transformation projects at Sanofi and Ipsen, as well as serving as General Manager for the Belgium–Luxembourg region at Ipsen and the biotech company Perha Pharmaceuticals. For the past two years, she has been advising biotech Chief Executive Officers and executive committees on clinical and commercial development of innovative product portfolios, with successful business development outcomes. Sophie holds a degree from ESSEC Business School. Amit Kohli has over 3 decades of leadership experience operating at the intersection of science, finance, and commercialization. Amit has extensive experience in the diabetes therapy area, having held senior roles at Sanofi (1997-2010) and Becton Dickinson (2011-2016) where he launched diabetes-related products across developed and emerging markets growing them to multi-billion euros in revenue. Lately, as Chief Executive Officer of privately held biotech, Antev (2020 onwards), he led the company’s $75M sale to Medicus. Mr. Kohli has held Global and regional leadership roles at Pharnext, Eurofins, Becton Dickinson, and Sanofi, encompassing sales, marketing, finance, supply chain, and manufacturing. Mr. Kohli earned an M.B.A. in Finance from the Management Development Institute (MDI) Gurgaon, in India, and a Bachelor of Mechanical Engineering from the University of Pune in India. Alexandre Bragadir has been a Senior Investment Director at IPF Partners, a fund specializing in non-dilutive financing for innovative healthcare companies across Europe. He structures and oversees debt investments, having been involved with a dozen companies in the biotech, biopharma, medtech, and digital health sectors over the past six years. He began his career in 2003 in audit at Salustro Reydel before joining BNP Paribas, in strategic client coverage in Portugal, in structured finance in Paris, and in the commodity trade finance team in Geneva. Alexandre holds a degree from ESCP Europe.
お知らせ • May 28Poxel SA Announces New Clinical and Scientific Data on TWYMEEG® to Be Presented at the 68th Annual Meeting of the Japan Diabetes SocietyPOXEL SA announced that new clinical and scientific data on TWYMEEG will be presented at the 68th Annual Meeting of the Japan Diabetes Society (JDS 2025), taking place from May 29 to 31, 2025, in Okayama, Japan. A total of 15 presentations, including results from 7 clinical trials, 3 post-hoc analyses and 5 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. These findings further confirm TWYMEEG's efficacy in monotherapy and combination therapies, safety, dual mechanism of action and potential benefits in specific patient populations. Main topics include: TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) study (Phase 4 study): confirmation of TWYMEEG®? efficacy and safety in diabetic patients with renal impairment; FAMILIAR Study: confirmation of TWYMEE G®? efficacy and safety in combination with DPP-4 inhibitors; PARADIME Clamp: confirmation of TWYMeeG®? dual mechanism of action in diabetic patients - clinical data showing effects on insulin sensitivity (clamp part) and glucose stimulated insulin secretion (OGTT part); PARADIME TIR: confirmation of TWYMCEG®? effects on glucose variability; PET/MRI Study: confirmation of TWY MEEG®? effect on glucose excretion in the gut.
お知らせ • Apr 08Poxel SA Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG®? Package Insert to Include Type 2 Diabetes Patients with Renal ImpairmentPOXEL SA announced that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved the revision of TWYMEEG®? package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m2. This approval follows positive topline results from the post-marketing clinical study TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) in Japanese type 2 diabetic patients with renal impairment, which confirmed TWYMEEG®®?'s safety and tolerability profile, as announced last August1. Based on these results, discussions with the Japanese regulatory authorities were initiated by Sumitomo Pharma, resulting in the approval that will be officially implemented by Sumitomo Pharma as of April 8, 2025.
お知らせ • Jan 24+ 4 more updatesPoxel S.A. to Report First Half, 2025 Results on Sep 23, 2025Poxel S.A. announced that they will report first half, 2025 results on Sep 23, 2025
お知らせ • Apr 30Poxel S.A. to Report Fiscal Year 2025 Results on Jun 15, 2026Poxel S.A. announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Jun 15, 2026
お知らせ • Nov 27Poxel S.A., Annual General Meeting, Dec 11, 2025Poxel S.A., Annual General Meeting, Dec 11, 2025. Location: 12 cours de verdun rambaud esplanade de la gare, lyon France
お知らせ • Aug 01+ 1 more updatePoxel S.A. Announces Board ChangesPoxel SA announced significant changes within its Board of Directors following the filing for reorganization proceedings. All the current directors of the Company, Ms. Pascale Boissel, Mr. Richard Kender, Mr. Thomas Kuhn, and Mr. Khoso Baluch, submitted their resignations with immediate effect as of July 31, 2025. The Board of Directors decided to replace them individually by co-optation with immediate effect by the following new directors: Ms. Sophie Jacq Lapointe, Mr. Nicolas Trouche, Mr. Amit Kohli, and Mr. Alexandre Bragadir. These co-optations will be subject to ratification at the next general meeting of shareholders of the Company. Ms. Sophie Jacq Lapointe has been appointed by the new Board of Directors as Chairman of the Board of Directors, succeeding Mr. Khoso Baluch. Sophie Jacq Lapointe has over 20 years of experience in the pharmaceutical industry, having held numerous executive roles and contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology. She has led or been involved in more than twenty product launches in France, across Europe, and in emerging markets, during her time at Roche, Sanofi, and Ipsen. This includes major R&D transformation projects at Sanofi and Ipsen, as well as serving as General Manager for the Belgium–Luxembourg region at Ipsen and the biotech company Perha Pharmaceuticals. For the past two years, she has been advising biotech Chief Executive Officers and executive committees on clinical and commercial development of innovative product portfolios, with successful business development outcomes. Sophie holds a degree from ESSEC Business School. Amit Kohli has over 3 decades of leadership experience operating at the intersection of science, finance, and commercialization. Amit has extensive experience in the diabetes therapy area, having held senior roles at Sanofi (1997-2010) and Becton Dickinson (2011-2016) where he launched diabetes-related products across developed and emerging markets growing them to multi-billion euros in revenue. Lately, as Chief Executive Officer of privately held biotech, Antev (2020 onwards), he led the company’s $75M sale to Medicus. Mr. Kohli has held Global and regional leadership roles at Pharnext, Eurofins, Becton Dickinson, and Sanofi, encompassing sales, marketing, finance, supply chain, and manufacturing. Mr. Kohli earned an M.B.A. in Finance from the Management Development Institute (MDI) Gurgaon, in India, and a Bachelor of Mechanical Engineering from the University of Pune in India. Alexandre Bragadir has been a Senior Investment Director at IPF Partners, a fund specializing in non-dilutive financing for innovative healthcare companies across Europe. He structures and oversees debt investments, having been involved with a dozen companies in the biotech, biopharma, medtech, and digital health sectors over the past six years. He began his career in 2003 in audit at Salustro Reydel before joining BNP Paribas, in strategic client coverage in Portugal, in structured finance in Paris, and in the commodity trade finance team in Geneva. Alexandre holds a degree from ESCP Europe.
お知らせ • May 28Poxel SA Announces New Clinical and Scientific Data on TWYMEEG® to Be Presented at the 68th Annual Meeting of the Japan Diabetes SocietyPOXEL SA announced that new clinical and scientific data on TWYMEEG will be presented at the 68th Annual Meeting of the Japan Diabetes Society (JDS 2025), taking place from May 29 to 31, 2025, in Okayama, Japan. A total of 15 presentations, including results from 7 clinical trials, 3 post-hoc analyses and 5 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. These findings further confirm TWYMEEG's efficacy in monotherapy and combination therapies, safety, dual mechanism of action and potential benefits in specific patient populations. Main topics include: TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) study (Phase 4 study): confirmation of TWYMEEG®? efficacy and safety in diabetic patients with renal impairment; FAMILIAR Study: confirmation of TWYMEE G®? efficacy and safety in combination with DPP-4 inhibitors; PARADIME Clamp: confirmation of TWYMeeG®? dual mechanism of action in diabetic patients - clinical data showing effects on insulin sensitivity (clamp part) and glucose stimulated insulin secretion (OGTT part); PARADIME TIR: confirmation of TWYMCEG®? effects on glucose variability; PET/MRI Study: confirmation of TWY MEEG®? effect on glucose excretion in the gut.
お知らせ • Apr 08Poxel SA Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG®? Package Insert to Include Type 2 Diabetes Patients with Renal ImpairmentPOXEL SA announced that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved the revision of TWYMEEG®? package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m2. This approval follows positive topline results from the post-marketing clinical study TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) in Japanese type 2 diabetic patients with renal impairment, which confirmed TWYMEEG®®?'s safety and tolerability profile, as announced last August1. Based on these results, discussions with the Japanese regulatory authorities were initiated by Sumitomo Pharma, resulting in the approval that will be officially implemented by Sumitomo Pharma as of April 8, 2025.
お知らせ • Jan 24+ 4 more updatesPoxel S.A. to Report First Half, 2025 Results on Sep 23, 2025Poxel S.A. announced that they will report first half, 2025 results on Sep 23, 2025
お知らせ • Nov 08Poxel S.A. Provides Revenue Guidance for the Full Year 2024Poxel S.A. provided revenue guidance for the full year 2024. The company to see the good sales trajectory for TWYMEEG in Japan, which should lead to the achievement of JPY 5 billion net sales in the coming months, at which point, Poxel will be entitled to 10% royalties on all TWYMEEG net sales and a sales-based payment of JPY 500 million (EUR 3.1 million).These amounts, based on recent royalty monetization agreement, will serve to start repayment of bonds to OrbiMed. Additionally, Poxel will benefit from the residual amount of the reserve deposit made under the terms of the agreement with OrbiMed, in addition to the USD 42.5 million proceeds received upon closing.
お知らせ • Oct 24Poxel S.A., Annual General Meeting, Nov 28, 2024Poxel S.A., Annual General Meeting, Nov 28, 2024. Location: hotel mercure lyon, centre chateau perrache, 12 cours de verdun rambaud esplanade de la gare, lyon France
お知らせ • Aug 07Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in JapanSumitomo Pharma Co., Ltd. and POXEL SA announced topline results obtained from a post-marketing clinical study, TWINKLE (TWYMEEG in diabetic patients with renal impairment: A post-marketing long-term study) (“the Study”), in Japanese type 2 diabetic patients with renal impairment for TWYMEEG Tablets 500 mg (generic name: imeglimin hydrochloride, “the Drug”) being sold in Japan, based on the Risk Management Plan. The Study was an open-label, uncontrolled, long-term study in 60 Japanese type 2 diabetic patients with renal impairment, who had no experience of type 2 diabetes treatment other than diet and exercise therapy or insufficient glycemic management in monotherapy with a hypoglycemic agent excluding insulin formulation. The Drugwas administered at 500 mg twice-daily to patients with moderate and severe renal impairment, characterized by an estimated glomerular filtration rate (eGFR) between 15 mL/min/1.73 m2 or higher to less than 45 mL/min/1.73 m2, or at 500 mg once-daily to patients with end-stage renal disease, characterized by an eGFR less than 15 mL/min/1.73m2, in monotherapy or in combination therapy with a hypoglycemic agent excluding insulin formulation, to evaluate safety and tolerability when administered orally for 52 weeks. The Drug was observed to be safe and well tolerated in Japanese type 2 diabetic patients with renal impairment and no significant differences were found in the incidence of adverse events, their types and severities in this study from previous clinical studies. Specifically, most of the adverse events were mild or moderate in severity. The incidence of serious adverse events was 16.7% (10 of 60 subjects) and causality with the Drug could be ruled out in all cases. Incidence of adverse events leading to study treatment discontinuation was also limited (4 of 60 subjects). At present, administration of the Drug is not recommended for patients with renal impairment with eGFR less than 45 mL/min/1.73m2. Based on the results of the Study, Sumitomo Pharma is planning to conduct discussions with the regulatory authorities in Japan, on revising the package insert in fiscal 20241 for patients with renal impairment with eGFR less than 45 mL/min/1.73m2.
お知らせ • May 16Poxel S.A., Annual General Meeting, Jun 21, 2023Poxel S.A., Annual General Meeting, Jun 21, 2023, at 09:00 Central European Standard Time. Location: Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bonnel, 69003 LYON, France. Lyon France
お知らせ • Jan 04+ 3 more updatesPoxel S.A. to Report Q3, 2023 Results on Nov 08, 2023Poxel S.A. announced that they will report Q3, 2023 results on Nov 08, 2023
